( es than the Pegasys treatmentgroup. Am...)Human Genome Sciences Announces Positive Final Results Of Phase 2b,Trial of Albuferon,Health

es than the Pegasys treatment group. Among heavier patients (>75 kg) who were treatment-adherent, 71.2% of those in the combined groups receiving Albuferon every two weeks achieved SVR, versus 53.3% for patients receiving Pegasys once a week. The ability to maintain efficacy in heavier patients is of particular importance in certain markets, including the United States, where a large percentage of patients weigh more than 75 kg.

Top-Line Final Results by Treatment Group

The top-line final results of the Phase 2b trial at Week 24 following the completion of therapy include the following SVR rates and other findings:

    Albuferon 900-mcg Every Two Weeks (Albuferon 900 Q2w)


    -- Based on an intention-to-treat (ITT) analysis, 58.5% of patients in the

       Albuferon 900 Q2w treatment group achieved SVR, vs. 57.9% for Pegasys

       administered every week.

    -- In heavier patients (>75 kg) who were treatment-adherent, 74.2% of

       those in the Albuferon 900 Q2w treatment group achieved SVR, versus

       53.3% for Pegasys.

    -- Among all treatment-adherent patients in the Albuferon 900 Q2w

       treatment group, 72.3% achieved SVR, versus 66.7% for Pegasys.

    -- Based on the SF-36 Health Survey, patients in the Albuferon 900 Q2w

       treatment group reported less impairment of health-related quality of

       life, compared with patients in the Pegasys treatment group, as

       measured by both physical component and mental component SF-36 summary

       measures at all time-points throughout the 48-week treatment period.

    -- Fewer working patients in the Albuferon 900 Q2w treatment group

       reported missing 7 days or more of work during the month prior to their

       visits at Weeks 12 and 24, vs. the Pegasys group (Week 12:  3.0% for

       Albuferon 900 Q2w vs. 19.2% for Pegasys; Week 24:  5.8% for Albuferon

       900 Q2w, vs. 22.4% for Pegasys).

    -- The rate of discontinuations due to adverse e
'"/>




Page: 1 2 3 4 5 6 7 8 
Related medicine technology :

1. Testing for Human Papillomavirus
2. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs
Published Study on Culture Blood-Forming Stem Cells from Human Fat
Tissue as Supporting Near Term Benefits of Banking Adipose (Fat)
Derived Stem Cells
3. Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog
Liraglutide, Brings Patients to A1c Target
4. Advanced Cell Technology Develops First Human Embryonic Stem Cell
Line without Destroying an Embryo
5. Modigene Announces Successful Completion of Pharmacokinetic &
Pharmacodynamic Pre-Clinical Experiments for Proprietary
Long-Acting Human Growth Hormone, Long-acting Interferon Beta and
Long-acting Erythropoietin
6. Second Successful Quigley QR-443 Study Suggests Method of Action
Relevant to Broad Range of Chronic Inflammatory Diseases - Human
Study to Follow -
7. Research Documents Scalable Production, Survival Following
Engraftment and Positive Impact on Cardiac Function in Infarcted
Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for
Heart Failure
8. Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B
Showed Significant Reductions in Disease Activity in Patients with
Active Systemic Lupus Erythematosus
9. NCI Researchers Discover Genes That Are Turned on at High Levels in
Tumor-associated Blood Vessels of Mice and Humans
10. Research Indicates Gerons Human Embryonic Stem Cell-Based
Therapeutic for Spinal Cord Injury Evades Direct Attack by the
Human Immune System
11. Mymetics HIV Vaccine Demonstrates First-Ever Production of
Neutralizing IgA Antibodies in Non-Human Primate Model